Therapeutic Focus
As an international biopharmaceutical company, we believe that the best way to meet patient needs is always through valuable collaboration. At Chiesi, our strong expertise in R&D and our global presence drive the development of impactful commercial partnerships. These partnerships are the driving force behind revolutionary discoveries in our business areas: Air, Rare, and Care.
- Asthma and COPD
- Interstitial lung disease (e.g. IPF)
- Pulmonary arterial hypertension (PAH)
- Non-CF Bronchiectasis
- Small molecules
- Biologics
- RNA therapeutics
- From early research to late-stage/commercial assets
- Inborn Errors of Metabolism: primarily Lysosomal Storage Disorders
- Rare IMMUNODEFICIENCIES
- Rare HEMOGLOBINOPATHIES
- Rare Endocrinology/Cardio-metabolic
- Rare Dermatology
- Rare Ophtha, back of the eye indications
- Small molecules
- Biologics
- RNA therapeutics
- Gene editing
- From early research to late-stage/commercial assets
- Hospital acute & critical care
- Solid organ transplant
- Neonatal conditions including BPD/CLD, PH-secondary to BPD, PPHN, HIE, seizures, NEC, intestinal
malabsorption and other conditions related to poor growth and nutritional support, sepsis
- Small molecules
- Biologics
- RNA therapeutics (neo only)
- Gene editing (neo only)
- Hospital acute & critical care and solid organ transplant: commercial assets or late-stage post-PoC
- Neonatal: from early research to late-stage/commercial assets
